Therefore, we downregulated the activities of these receptors by antagonists that are conventionally used to block their activities, in research and also in the clinic (e.g., the CCR5 antagonist); the inhibitors were used in concentrations that were selected by titration analyses, guaranteeing no effects on cancer cell viability (or partial effect in the case of CCR2 inhibitor, as described in Section 4). The gene discussed is CCR5; the disease is cancer.